Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 19, 2022

SELL
$7.02 - $13.33 $2.8 Million - $5.32 Million
-399,103 Closed
0 $0
Q3 2021

Oct 19, 2021

SELL
$11.32 - $16.63 $121,984 - $179,204
-10,776 Reduced 2.63%
399,103 $4.55 Million
Q2 2021

Aug 09, 2021

SELL
$15.16 - $18.97 $341,009 - $426,711
-22,494 Reduced 5.2%
409,879 $6.56 Million
Q1 2021

May 13, 2021

SELL
$13.12 - $20.9 $451,223 - $718,792
-34,392 Reduced 7.37%
432,373 $7.73 Million
Q4 2020

Jan 19, 2021

SELL
$9.12 - $14.49 $502,548 - $798,456
-55,104 Reduced 10.56%
466,765 $6.31 Million
Q3 2020

Nov 16, 2020

BUY
$10.46 - $14.46 $167,600 - $231,692
16,023 Added 3.17%
521,869 $6.14 Million
Q2 2020

Jul 17, 2020

BUY
$12.0 - $16.13 $1.02 Million - $1.38 Million
85,307 Added 20.29%
505,846 $7.47 Million
Q1 2020

Apr 16, 2020

SELL
$11.84 - $25.52 $1.46 Million - $3.16 Million
-123,676 Reduced 22.73%
420,539 $5.68 Million
Q4 2019

Feb 14, 2020

SELL
$17.72 - $25.1 $37,938 - $53,739
-2,141 Reduced 0.39%
544,215 $13.2 Million
Q3 2019

Nov 14, 2019

BUY
$18.41 - $28.0 $4.06 Million - $6.17 Million
220,293 Added 67.56%
546,356 $10.5 Million
Q2 2019

Aug 14, 2019

BUY
$28.97 - $48.21 $14,224 - $23,671
491 Added 0.15%
326,063 $9.64 Million
Q1 2019

May 07, 2019

BUY
$36.32 - $49.25 $7.69 Million - $10.4 Million
211,699 Added 185.91%
325,572 $15.5 Million
Q4 2018

Jan 25, 2019

SELL
$33.0 - $60.04 $14.5 Million - $26.4 Million
-439,372 Reduced 79.42%
113,873 $4.11 Million
Q3 2018

Oct 30, 2018

BUY
$56.15 - $73.9 $10.5 Million - $13.9 Million
187,810 Added 51.39%
553,245 $34.1 Million
Q2 2018

Aug 03, 2018

BUY
$47.85 - $70.45 $17.5 Million - $25.7 Million
365,435 New
365,435 $24.7 Million

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Frontier Capital Management CO LLC Portfolio

Follow Frontier Capital Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frontier Capital Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frontier Capital Management CO LLC with notifications on news.